Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rituximab Clear all
Recruiting Phase 1Phase 2 Interventional

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

NCT07294677
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

NCT00143871
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
Rituximab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

NCT01573533
View directory record Official record
Conditions
Primary Focal Segmental Glomerulosclerosis
Interventions
Rituximab
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

NCT00005652
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

NCT00069758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
SDX-105
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

NCT02514772
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
39
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

NCT00567229
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, lenalidomide, microarray analysis, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01082939
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Alemtuzumab, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

NCT00079443
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
romidepsin, rituximab, fludarabine phosphate, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
tafasitamab, rituximab, lenalidomide, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
38
States / cities
Concord, California • Greenbrae, California • Pasadena, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

NCT00415506
View directory record Official record
Conditions
Scleritis, Orbital Disease
Interventions
Rituximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

NCT00072514
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
gemcitabine hydrochloride, carboplatin, dexamethasone, rituximab
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Early Phase 1 Interventional

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

NCT01022021
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Bendamustine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 28, 2026, 9:42 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Best available Treatment (BAT)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

NCT03023878
View directory record Official record
Conditions
High-risk Diffuse Large B-Cell Lymphoma
Interventions
Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions
Iptacopan, Placebo, Rituximab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Mesa, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

NCT01326702
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Bendamustine Hydrochloride, Pharmacological Study, Rituximab, Veliparib
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

NCT00216762
View directory record Official record
Conditions
Urticaria
Interventions
Rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

NCT00193479
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

NCT00001805
View directory record Official record
Conditions
Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions
Rituximab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Not applicable Interventional Results available

Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia

NCT01230788
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, ALL
Interventions
rituximab
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

NCT00085696
View directory record Official record
Conditions
B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
Interventions
VELCADE and rituximab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Fort Myers, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Oct 28, 2026, 9:42 PM EDT